Xencor Inc (XNCR)
About Xencor Inc
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $125.6M
- Net income
- -$91.9M
- Total assets
- $875.5M
- Market cap
- $872.6M
- Operating margin
- -141.4%
- Net margin
- -73.4%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $125.6M
- Operating expenses
- $303.1M
- Operating income
- -$177.5M
- Income tax
- $2.5M
- Net income
- -$92.1M
- EPS (basic)
- $-1.24
- EPS (diluted)
- $-1.24
Balance sheet
- Total assets
- $875.5M
- Current assets
- $599.8M
- Total liabilities
- $239.9M
- Current liabilities
- $95.9M
- Shareholders’ equity
- $635.6M
Cash flow
- Operating cash flow
- -$135.1M
- Investing cash flow
- $140.0M
- Financing cash flow
- $8.2M
- Net cash flow
- $13.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $872.6M
- EPS (diluted)
- $-1.24
- Shares outstanding
- 44.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Dec 3, 2013
Xencor Inc (XNCR) Stock Price
- Reported a net loss of $91.9M in FY2025.
- Revenue grew 2% from FY2020 to FY2025.
- Trading 5% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Xencor Inc.
Write a review
News about Xencor Inc
News & sentiment via Polygon.io
Xencor Inc: frequently asked questions
Is Xencor Inc an American company?
Xencor Inc is a US-based company headquartered in Pasadena, California, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Xencor Inc headquartered?
Xencor Inc is headquartered in Pasadena, California, United States.
Is Xencor Inc publicly traded?
Yes — Xencor Inc is a publicly traded company. Its stock trades under the ticker symbol XNCR on the NASDAQ.
What does Xencor Inc do?
Xencor Inc is an American Pharmaceuticals company in the Health & Beauty sector.
